International Stem Cell Corp (ISCO)

International Stem Cell Corp. is a clinical-stage biotechnology company listed on OTC Markets under the symbol ISCO. The company focuses on developing therapeutic and biomedical products in the United States, Asia, Europe, and other international markets. Its research pipeline includes ISC-hpNSC, a neural stem cell program that has completed a Phase I clinical trial in Parkinson’s disease and is also being studied for potential use in stroke, traumatic brain injury, and Alzheimer’s disease. Beyond its clinical programs, the company markets anti-aging skin care products under the ProPlus brand and supplies human cell culture products used in research across areas such as skin disease, toxicology, wound healing, cardiovascular disease, cancer, respiratory conditions, regenerative medicine, and other biomedical studies. International Stem Cell Corp. was founded in 2001 and is headquartered in San Diego, California.

Jump directly to the stock analysis sections supported by the latest available data.